Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01993849 · ClinicalTrials.gov registry record · Phase 3
Use of N-Acetylcysteine (NAC) in Fingernail Biting
A Phase 3 study, sponsored by Kevin Gray, MD.
- Completed
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT01993849: Completed Phase 3 study, sponsored by Kevin Gray, MD.
NCT01993849 is a Phase 3 study that has completed, run by Kevin Gray, MD. The registered enrollment target is 23 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01993849, a Phase 3 study, has completed, sponsored by Kevin Gray, MD.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
To conduct a pilot randomized placebo-controlled feasibility trial of N-acetylcysteine (NAC) in onychophagia, preliminarily assessing the tolerability and effects of this pharmacotherapy on young adults who bite their fingernails. It is proposed that NAC will help decrease fingernail biting.
Primary Outcome
Ability to enroll the goal sample within one year; we are interested in the feasibility of sufficient enrollment and data collection within a given period of time.
Interventions
- OTHER Placebo
- DRUG N-Acetylcysteine (NAC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
What the finished NCT01993849 record still lists
NCT01993849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01993849 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01993849 about?
NCT01993849 is a clinical study titled "Use of N-Acetylcysteine (NAC) in Fingernail Biting". To conduct a pilot randomized placebo-controlled feasibility trial of N-acetylcysteine (NAC) in onychophagia, preliminarily assessing the tolerability and effects of this pharmacotherapy on young adults who bite their fingernails. It is proposed that NAC will help decrease fingernail biting.
What is the current status of trial NCT01993849?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2013-10. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01993849?
The interventions under investigation include: Placebo (OTHER), N-Acetylcysteine (NAC) (DRUG).
Who is sponsoring clinical trial NCT01993849?
This trial is sponsored by Kevin Gray, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01993849's enrollment target sits among peer trials
23 1952nd of 2000 higher than 48 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia